Analysis contradicts self-report data on PSA testing utilization

The use of PSA testing by urologists and primary care physiciansis much lower than that suggested by practitioner- and patient-based publishedself-report estimates, according to a study of national clinic-report dataconducted by urologists at the University of Michigan, Ann Arbor.

Related Videos

Related Content

Advertisement

December 9th 2024

High cystectomy-free survival seen with nadofaragene treatment in NMIBC

Benjamin P. Saylor

"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 9th 2024

What drives malpractice lawsuits involving testicular cancer?

Benjamin P. Saylor

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 6th 2024

FDA grants priority review to durvalumab for muscle-invasive bladder cancer

Benjamin P. Saylor

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

Related Content

Advertisement

December 9th 2024

High cystectomy-free survival seen with nadofaragene treatment in NMIBC

Benjamin P. Saylor

"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 9th 2024

What drives malpractice lawsuits involving testicular cancer?

Benjamin P. Saylor

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 6th 2024

FDA grants priority review to durvalumab for muscle-invasive bladder cancer

Benjamin P. Saylor

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.